NK cells restrain spontaneous antitumor CD8+ T cell priming through pd-1/pd-l1 interactions with dendritic cells

Journal of Immunology

Volumn 197, Issue 3, 2016, Pages 953-961

  Raffo Iraolagoitia, Ximena L ^a   Spallanzani, Raul G ^a   Torres, Nicolás I ^a   Araya, Romina E ^a   Ziblat, Andrea ^a   Domaica, Carolina I ^a   Sierra, Jessica M ^a   Nuñez, Sol Y ^a   Secchiari, Florencia ^a   Gajewski, Thomas F ^b   Zwirner, Norberto W ^a,c   Fuertes, Mercedes B ^a,c  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPH NODE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION; ANIMAL; C57BL MOUSE; CELL SEPARATION; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SEPARATION; CROSS-PRIMING; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84979518723     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502291     Document Type: Article

References (51)

1. Lanier, L. L. 2008. Evolutionary struggles between NK cells and viruses. Nat. Rev. Immunol. 8: 259-268.
2. Moretta, L., C. Bottino, D. Pende, R. Castriconi, M. C. Mingari, and A. Moretta. 2006. Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18: 151-158.
3. Zwirner, N. W., and C. I. Domaica. 2010. Cytokine regulation of natural killer cell effector functions. Biofactors 36: 274-288.
4. Ziblat, A., C. I. Domaica, R. G. Spallanzani, X. L. Iraolagoitia, L. E. Rossi, D. E. Avila, N. I. Torres, M. B. Fuertes, and N. W. Zwirner. 2015. IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur. J. Immunol. 45: 192-202.
5. Girart, M. V., M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner. 2007. Engagement of TLR3, TLR7, and NKG2D regulate IFN-γamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179: 3472-3479.
6. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
7. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
8. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
9. Moretta, A., E. Marcenaro, S. Sivori, M. Della Chiesa, M. Vitale, and L. Moretta. 2005. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 26: 668-675.
10. Walzer, T., M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier. 2005. Naturalkiller cells and dendritic cells: l'union fait la force. Blood 106: 2252-2258.
11. Martín-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-γamma for T(H)1 priming. Nat. Immunol. 5: 1260-1265.
12. Cook, K. D., and J. K. Whitmire. 2013. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J. Immunol. 190: 641-649.
13. + T cell responses during chronic viral infection to limit autoimmunity. Immunity 41: 646-656.
14. + T-cell immunity. Proc. Natl. Acad. Sci. USA 109: 1210-1215.
15. + T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120: 1925-1938.
16. Laffont, S., C. Seillet, J. Ortaldo, J. D. Coudert, and J. C. Guéry. 2008. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells. Blood 112: 661-671.
17. + T cells in mice. Endocrinology 153: 4367-4379.
18. Rabinovich, B. A., J. Li, J. Shannon, R. Hurren, J. Chalupny, D. Cosman, and R. G. Miller. 2003. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 170: 3572-3576.
19. Cerboni, C., A. Zingoni, M. Cippitelli, M. Piccoli, L. Frati, and A. Santoni. 2007. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110: 606-615.
20. + T cell priming in the absence of NK cells leads to enhanced memory responses. J. Immunol. 186: 3304-3308.
21. Peppa, D., U. S. Gill, G. Reynolds, N. J. Easom, L. J. Pallett, A. Schurich, L. Micco, G. Nebbia, H. D. Singh, D. H. Adams, et al. 2013. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 210: 99-114.
22. + T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 26: 593-604.
23. Waggoner, S. N., M. Cornberg, L. K. Selin, and R. M. Welsh. 2011. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481: 394-398.
24. Andrews, D. M., M. J. Estcourt, C. E. Andoniou, M. E. Wikstrom, A. Khong, V. Voigt, P. Fleming, H. Tabarias, G. R. Hill, R. G. van der Most, et al. 2010. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J. Exp. Med. 207: 1333-1343.
25. Hayakawa, Y., V. Screpanti, H. Yagita, A. Grandien, H. G. Ljunggren, M. J. Smyth, and B. J. Chambers. 2004. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 172: 123-129.
26. Gajewski, T. F., H. Schreiber, and Y. X. Fu. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14: 1014-1022.
27. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
28. Blank, C., T. F. Gajewski, and A. Mackensen. 2005. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54: 307-314.
29. Park, S. J., H. Namkoong, J. Doh, J. C. Choi, B. G. Yang, Y. Park, and Y. Chul Sung. 2014. Negative role of inducible PD-1 on survival of activated dendritic cells. J. Leukoc. Biol. 95: 621-629.
30. Driessens, G., J. Kline, and T. F. Gajewski. 2009. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229: 126-144.
31. Mahoney, K. M., G. J. Freeman, and D. F. McDermott. 2015. The next immunecheckpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin. Ther. 37: 764-782.
32. Herbst, R. S., J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid, M. S. Gordon, J. A. Sosman, D. F. McDermott, J. D. Powderly, S. N. Gettinger, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567.
33. Teng, M. W., S. F. Ngiow, A. Ribas, and M. J. Smyth. 2015. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75: 2139-2145.
34. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204: 49-55.
35. Rossi, L. E., D. E. Avila, R. G. Spallanzani, A. Ziblat, M. B. Fuertes, L. Lapyckyj, D. O. Croci, G. A. Rabinovich, C. I. Domaica, and N. W. Zwirner. 2012. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J. Leukoc. Biol. 91: 321-331.
36. Joshi, N. S., W. Cui, A. Chandele, H. K. Lee, D. R. Urso, J. Hagman, L. Gapin, and S. M. Kaech. 2007. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
37. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763.
38. Deniz, G., G. Erten, U. C. Kucuksezer, D. Kocacik, C. Karagiannidis, E. Aktas, C. A. Akdis, and M. Akdis. 2008. Regulatory NK cells suppress antigen-specific T cell responses. J. Immunol. 180: 850-857.
39. Mailloux, A. W., and M. R. Young. 2009. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol. 182: 2753-2765.
40. Youn, J. I., and D. I. Gabrilovich. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40: 2969-2975.
41. Park, Y. J., B. Song, Y. S. Kim, E. K. Kim, J. M. Lee, G. E. Lee, J. O. Kim, Y. J. Kim, W. S. Chang, and C. Y. Kang. 2013. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells. Cancer Res. 73: 5669-5681.
42. + T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208: 2005-2016.
43. Chiossone, L., J. Chaix, N. Fuseri, C. Roth, E. Vivier, and T. Walzer. 2009. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113: 5488-5496.
44. Robbins, S. H., K. B. Nguyen, N. Takahashi, T. Mikayama, C. A. Biron, and L. Brossay. 2002. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J. Immunol. 168: 2585-2589.
45. Omi, A., Y. Enomoto, T. Kiniwa, N. Miyata, and A. Miyajima. 2014. Mature resting Ly6C(high) natural killer cells can be reactivated by IL-15. Eur. J. Immunol. 44: 2638-2647.
46. Stojanovic, A., N. Fiegler, M. Brunner-Weinzierl, and A. Cerwenka. 2014. CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells. J. Immunol. 192: 4184-4191.
47. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
48. Fogel, L. A., W. M. Yokoyama, and A. R. French. 2013. Natural killer cells in human autoimmune disorders. Arthritis Res. Ther. 15: 216.
49. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
50. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
51. Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, J. D. Coudert, M. Desbois, F. Ghiringhelli, S. Viaud, B. Ryffel, H. Yagita, et al. 2012. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72: 2757-2767.